Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$5.40
$0.17(3.15%)
At close: 4:00 PM EDT
$5.40
$0.17(3.15%)
Day’s Range― - ―
52-Week Range$2.94 - $7.32
Previous CloseN/A
Volume2.29M
Average Volume (3M)4.56M
Market Cap
$2.35B
Enterprise Value$2.42K
Total Cash (Recent Filing)$38.21M
Total Debt (Recent Filing)$98.34M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 05, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding358,035,250
10 Day Avg. Volume3,165,004
30 Day Avg. Volume4,563,932
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$124.32M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue And AdoptionRapid revenue growth and increasing patient completion of the four-dose course indicate meaningful early product-market adoption. Sustained treatment uptake could create a commercial base that reduces dependence on grants and licensing revenue.
Reimbursement And Market ProtectionBroad payer access and a permanent reimbursement code lower adoption friction for providers and patients. FDA market exclusivity through 2032 also protects the commercial opportunity and supports durable revenue visibility.
Durable Clinical DifferentiationLong-lasting complete responses can differentiate PAPZIMEOS from alternatives and strengthen physician confidence in treatment value. The same platform validation may also improve the prospects of Precigen’s broader engineered therapy pipeline.
Bears Say
Persistent Cash ConsumptionLarge operating and free-cash-flow deficits show that the business has not yet funded itself consistently. Continued investment in commercialization and development may require external capital before the targeted cash-flow breakeven.
High Leverage And Interest BurdenDebt materially exceeds the company’s equity base, leaving limited financial cushion if commercialization underperforms or collections are delayed. Interest expense also consumes cash that could otherwise support research, sales, or operations.
Unproven Durable ProfitabilityAlthough Q2 was profitable, historical losses and elevated launch spending make earnings durability uncertain. Margin normalization, rising SG&A, and planned R&D growth could materially reduce profits until revenue scales beyond the current launch phase.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $2.94 and its highest was $7.32 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $2.35B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on Aug 04, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.062.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Undervalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is 0.05.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 358,035,250 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 5.513%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (233.33% Upside)
$18.00 (233.33% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
237.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
67.13%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS driven by exceptional Q2 revenue growth (>145% QoQ), launch-to-date revenue >$78M, broad payer coverage (~315M lives), durable clinical responses (83% ongoing CR >3 years), and attainment of profitability for the quarter and first half of 2026. Operational and financial risks noted include normalization of gross margins after remaining prelaunch inventory is consumed, reliance on accounts receivable collections and existing debt interest expense, rising commercial and future R&D spend, and limited public granularity on exact account activation counts and non-hub patient visibility. Overall, the positive revenue, profitability, coverage, and durability developments materially outweigh the manageable operational and financial caveats.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$18.00
▲(233.33% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
35.41% Insiders
11.74% Mutual Funds
15.84% Other Institutional Investors
27.68% Public Companies and
Individual Investors